Fatty acid esters of phloridzin induce apoptosis of human liver cancer cells through altered gene expression

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Nair, Sandhya V G ^a   Ziaullah, ^a   Vasantha Rupasinghe, H P ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CASPASE 3; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; DOCOSAHEXAENOIC ACID; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ICOSAPENTAENOIC ACID; LINOLEIC ACID; LINOLENIC ACID; LIPASE B; OLEIC ACID; PHLORETIN; PHLORIZIN; PHLORIZIN ALPHA LINOLENIC ACID ESTER; PHLORIZIN DOCOSAHEXAENOIC ACID ESTER; PHLORIZIN EICOSAPENTAENOIC ACID ESTER; PHLORIZIN FATTY ACID ESTER; PHLORIZIN LINOLEIC ACID ESTER; PHLORIZIN OLEIC ACID ESTER; PHLORIZIN STEARIC ACID ESTER; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN BCL 2; SOMATOMEDIN B; SOMATOMEDIN C RECEPTOR; SORAFENIB; STEARIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; DNA BINDING PROTEIN; ESTER; FATTY ACID; LACTATE DEHYDROGENASE; LIPOCORTIN 5; TUMOR ANTIGEN;

ACYLATION; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER INHIBITION; CANDIDA ANTARCTICA; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; EPIGENETICS; GENE EXPRESSION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LIVER CANCER CELL LINE; MDA MB 231 CELL LINE; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEREOCHEMISTRY; THP 1 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CELL PROLIFERATION; DNA FRAGMENTATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANNEXIN A5; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA FRAGMENTATION; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; ESTERS; FATTY ACIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; L-LACTATE DEHYDROGENASE; LIVER NEOPLASMS; MEMBRANE POTENTIAL, MITOCHONDRIAL; PHLORHIZIN; RATS;

EID: 84907215533     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107149     Document Type: Article

References (48)

1. Stagos D, Amoutzias GD, Matakos A, Spyrou A, Tsatsakis AM, et al. (2012) Chemoprevention of liver cancer by plant polyphenols. Food and Chemical Toxicology 50: 2155-2170.
2. Pocobelli G, Cook LS, Brant R, Lee SS (2008) Hepatocellular carcinoma incidence trends in Canada: analysis by birth cohort and period of diagnosis. Liver Int 28: 1272-1279.
3. Wild CP, Montesano R (2009) A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention. Cancer Lett 286: 22-28.
4. Pang R, Tse E, Poon RT (2006) Molecular pathways in hepatocellular carcinoma. Cancer Lett 240: 157-169.
5. Horgan AM, Dawson LA, Swaminath A, Knox JJ (2012) Sorafenib and radiation therapy for the treatment of advanced hepatocellular carcinoma. J Gastrointest Cancer 43: 344-348.
6. Granado-Serrano AB, Martin MA, Bravo L, Goya L, Ramos S (2012) Quercetin modulates Nrf2 and glutathione-related defenses in HepG2 cells: Involvement of p38. Chem Biol Interact 195: 154-164.
7. Huang SP, Chen JC, Wu CC, Chen CT, Tang NY, et al. (2009) Capsaicin-induced apoptosis in human hepatoma HepG2 cells. Anticancer Res 29: 165-174.
8. Glauert HP, Calfee-Mason K, Stemm DN, Tharappel JC, Spear BT (2010) Dietary antioxidants in the prevention of hepatocarcinogenesis: a review. Mol Nutr Food Res 54: 875-896.
9. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J (2005) Phlorizin: a review. Diabetes Metab Res Rev 21: 31-38.
10. Ridgway T, O'Reilly J, West G, Tucker G, Wiseman H (1997) Antioxidant action of novel derivatives of the apple-derived flavonoid phloridzin compared to oestrogen: relevance to potential cardioprotective action. Biochem Soc Trans 25: 106S.
11. Puel C, Quintin A, Mathey J, Obled C, Davicco MJ, et al. (2005) Prevention of bone loss by phloridzin, an apple polyphenol, in ovariectomized rats under inflammation conditions. Calcif Tissue Int 77: 311-318.
12. Boccia MM, Kopf SR, Baratti CM (1999) Phlorizin, a competitive inhibitor of glucose transport, facilitates memory storage in mice. Neurobiol Learn Mem 71: 104-112.
13. Jung E, Lee J, Huh S, Lee J, Kim YS, et al. (2009) Phloridzin-induced melanogenesis is mediated by the cAMP signaling pathway. Food Chem Toxicol 47: 2436-2440.
14. Rezk BM, Haenen GR, van der Vijgh WJ, Bast A (2002) The antioxidant activity of phloretin: the disclosure of a new antioxidant pharmacophore in flavonoids. Biochem Biophys Res Commun 295: 9-13.
15. Szliszka E, Czuba ZP, Mazur B, Paradysz A, Krol W (2010) Chalcones and dihydrochalcones augment TRAIL-mediated apoptosis in prostate cancer cells. Molecules 15: 5336-5353.
16. Miura T, Chiba M, Kasai K, Nozaka H, Nakamura T, et al. (2008) Apple procyanidins induce tumor cell apoptosis through mitochondrial pathway activation of caspase-3. Carcinogenesis 29: 585-593.
17. Ziaullah, Bhullar KS, Warnakulasuriya SN, Rupasinghe HP (2013) Biocatalytic synthesis, structural elucidation, antioxidant capacity and tyrosinase inhibition activity of long chain fatty acid acylated derivatives of phloridzin and isoquercitrin. Bioorg Med Chem 21: 684-692.
18. Danihelová M, Viskupicová J, Sturdík E (2012) Lipophilization of flavonoids for their food, therapeutic and cosmetic applications. Acta Chimica Slovaca. 59.
19. Riss TL, Moravec RA (2004) Use of multiple assay endpoints to investigate the effects of incubation time, dose of toxin, and plating density in cell-based cytotoxicity assays. Assay Drug Dev Technol 2: 51-62.
20. Schley PD, Jijon HB, Robinson LE, Field CJ (2005) Mechanisms of omega-3 fatty acid-induced growth inhibition in MDA-MB-231 human breast cancer cells. Breast Cancer Res Treat 92: 187-195.
21. Zhivotosky B, Orrenius S (2001) Assessment of apoptosis and necrosis by DNA fragmentation and morphological criteria. Curr Protoc Cell Biol Chapter 18: Unit 18.13.
22. Llovet JM, Bruix J (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48: 1312-1327.
23. Cardile V, Lombardo L, Spatafora C, Tringali C (2005) Chemo-enzymatic synthesis and cell-growth inhibition activity of resveratrol analogues. Bioorg Chem 33: 22-33.
24. Baldisserotto A, Malisardi G, Scalambra E, Andreotti E, Romagnoli C, et al. (2012) Synthesis, antioxidant and antimicrobial activity of a new phloridzin derivative for dermo-cosmetic applications. Molecules 17: 13275-13289.
25. Lambert JD, Sang S, Hong J, Kwon SJ, Lee MJ, et al. (2006) Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of epigallocatechin-3-gallate. Drug Metab Dispos 34: 2111-2116.
26. Chen D, Wan SB, Yang H, Yuan J, Chan TH, et al. (2011) EGCG, green tea polyphenols and their synthetic analogs and prodrugs for human cancer prevention and treatment. Adv Clin Chem 53: 155-177.
27. Brown EM, Gill CI, McDougall GJ, Stewart D (2012) Mechanisms underlying the anti-proliferative effects of berry components in in vitro models of colon cancer. Curr Pharm Biotechnol 13: 200-209.
28. Gu FM, Li QL, Gao Q, Jiang JH, Huang XY, et al. (2011) Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3. World J Gastroenterol 17: 3922-3932.
29. Topcu Z (2001) DNA topoisomerases as targets for anticancer drugs. J Clin Pharm Ther 26: 405-416.
30. Larsen AK, Escargueil AE, Skladanowski A (2003) From DNA damage to G2 arrest: the many roles of topoisomerase II. Prog Cell Cycle Res 5: 295-300.
31. Watanuki A, Ohwada S, Fukusato T, Makita F, Yamada T, et al. (2002) Prognostic significance of DNA topoisomerase IIalpha expression in human hepatocellular carcinoma. Anticancer Res 22: 1113-1119.
32. El-Awady RA, Ali MM, Saleh EM, Ghaleb FM (2008) Apoptosis is the most efficient death-pathway in tumor cells after topoisomerase II inhibition. Saudi Med J 29: 558-564.33.
33. Constantinou A, Mehta R, Runyan C, Rao K, Vaughan A, et al. (1995) Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships. J Nat Prod 58: 217-225.
34. Faivre S, Djelloul S, Raymond E (2006) New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 33: 407-420.
35. Breuhahn K, Longerich T, Schirmacher P (2006) Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 25: 3787-3800.
36. Olsen SK, Brown RS, Siegel AB (2010) Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol 3: 55-66.
37. Zhou Q, Lui VWY, Yeo W (2011) Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncology 7: 1149-1167.
38. Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310.
39. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, et al. (2011) Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: Rationale and importance to inhibiting these pathways in human health. Oncotarget 2: 135-64.
40. Shapiro GI (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clinical Oncology 24: 1770-1783.
41. Zhang RG, Fang DC, Ning XY, Wang GA (2007) [Mechanisms of human telomerase reverse transcriptase RNAi which increases hepatocellular carcinoma cell apoptosis induced by TRAIL]. Zhonghua Gan Zang Bing Za Zhi 15: 32-36.
42. Naasani I, Oh-Hashi F, Oh-Hara T, Feng WY, Johnston J, et al. (2003) Blocking telomerase by dietary polyphenols is a major mechanism for limiting the growth of human cancer cells in vitro and in vivo. Cancer Res 63: 824-830.
43. Fulda S (2010) Evasion of apoptosis as a cellular stress response in cancer. Int J Cell Biol 2010: 370835.
44. Kang NJ, Shin SH, Lee HJ, Lee KW (2011) Polyphenols as small molecular inhibitors of signaling cascades in carcinogenesis. Pharmacology Therapeutics 130: 310-324.
45. Saitou Y, Shiraki K, Yamanaka T, Miyashita K, Inoue T, et al. (2005) Augmentation of tumor necrosis factor family-induced apoptosis by E3330 in human hepatocellular carcinoma cell lines via inhibition of NF kappa B. World J Gastroenterol 11: 6258-6261.
46. Delcuve GP, Khan DH, Davie JR (2012) Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin Epigenetics 4: 5.
47. Link A1, Balaguer F, Goel A (2010) Cancer chemoprevention by dietary polyphenols: promising role for epigenetics. Biochemical Pharmacology 80: 1771-92.
48. Hsu IC, Tokiwa T, Bennett W, Metcalf RA, Welsh JA, et al. (1993) p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis 14: 987-992.